From The Editor's Desk
Excluding Copycats
The partying days for gatecrashers is soon coming to an end. After considerable dithering, it now appears that the government has given a serious thought on ‘data exclusivity’ and is deciding to provide a four year exclusivity to innovators submitting data on pharmacology, toxicity, pharmacokinetics and clinical studies of a new product.

Edit Article
A timely pharmacopoeia
With the imminent formation of the Indian Pharmacopoeia Commission several questions are bound to be raised for which we need the answers in order to know whether we are about to see our own pharmacopoeia keeping pace with the compendia of other countries.